Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Vor BioPharma's Tremtelectogene Empogeditemcel?
Tremtelectogene Empogeditemcel is a gene-modified cell therapy commercialized by Vor BioPharma, with a leading Phase II program in Acute Myelocytic...
Data Insights
Risk adjusted net present value: What is the current valuation of Vor BioPharma's Tremtelectogene Empogeditemcel?
Tremtelectogene Empogeditemcel is a gene-modified cell therapy commercialized by Vor BioPharma, with a leading Phase II program in Acute Myelocytic...